Results 221 to 230 of about 245,298 (381)

Preferences Regarding Clinical Drug Trial Elements: A Nationally Representative Survey of Older Adults With Multimorbidity

open access: yesJournal of the American Geriatrics Society, EarlyView.
ABSTRACT Background Older adults with multimorbidity have been under‐represented in clinical drug trials. We sought to determine willingness to enroll in trials and preferences of older adults for learning about clinical trials, visit frequency, travel, locations, and testing.
Janice B. Schwartz   +3 more
wiley   +1 more source

Predictive Performance of Device‐Neonatal Skin Risk Assessment Scale to Evaluating Pressure Injuries Risk in the Neonates. An Observational Multicenter Study

open access: yesJournal of Clinical Nursing, EarlyView.
ABSTRACT Aim To assess the validity of a modified Neonatal Skin Risk Assessment scale (Dev‐NSARS) for neonatal pressure injuries (PIs) in the neonatal intensive care unit (NICU) and neonatal sub‐intensive care unit (NICU‐Sub) environment. Background Medical devices are the leading cause of pressure injuries (PIs) in neonates, a key cause of morbidity ...
Biagio Nicolosi   +6 more
wiley   +1 more source

GASTROESOPHAGEAL REFLUX (GER), APNEA (AP) AND BRADYCARDIA (BR) IN RESPONSE TO TREATMENT WITH NASAL CONTINUOUS POSITIVE AIRWAY PRESSURE (NCPAP).1136 [PDF]

open access: bronze, 1996
Excelsis Antonio   +5 more
openalex   +1 more source

Spastic Esophageal Disorders—How Much Muscle Should We Cut?

open access: yes
Digestive Endoscopy, EarlyView.
Siew‐Fung Hau, Hon Chi Yip
wiley   +1 more source

Use of dipeptidyl peptidase‐4 inhibitors is associated with lower risk of severe renal outcomes in pre‐dialysis patients with Type 2 diabetes

open access: yesJournal of Internal Medicine, EarlyView.
Abstract Objectives Patients with diabetes and Stage 5 chronic kidney disease (CKD) not on dialysis are susceptible to renal replacement therapy and severe complications. Among limited antidiabetic options in this vulnerable population, dipeptidyl peptidase‐4 (DPP‐4) inhibitors (DPP‐4i) are widely used; however, supporting evidence is scant.
Tung‐Ying Hung   +6 more
wiley   +1 more source

Risk factors associated with symptoms of gastroesophageal reflux [PDF]

open access: bronze, 1999
G. Richard Locke   +4 more
openalex   +1 more source

Home - About - Disclaimer - Privacy